ABL1 and prostate adenocarcinoma: Based on the results of CMap database inquiry, 15 types of small molecules drugs including ALK/ BCR-ABL/ BTK/ CDK /Met inhibitor, etc. were identified (Supplementary Table 16), eight small molecular drugs targeting TPM4 obtained (Supplementary Table 16), meaning that they have the potential to treat PRAD.